Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...

BofA Securities made adjustments to its outlook on AMD (NASDAQ:AMD) shares, lowering the price target to $135 from the previous $155, while keeping a Neutral stance on the company. According to ...

Recently, Absci entered into a strategic collaboration with Advanced Micro Devices Inc (NASDAQ:AMD) to enhance its AI drug discovery capabilities. Needham analyst Gil Blum writes that Absci sets ...

Needham initiates Absci coverage with a Buy rating and a $9 price target, citing robust proprietary technology. Absci’s partnerships with Merck, AstraZeneca, and Almirall provide milestone ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct ...

Morningstar brands and products Company Portfolio ...

(MENAFN- GlobeNewsWire - Nasdaq) $20 Million Equity investment from AMD Strengthens Absci's Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ...